mdl 72527 and metronidazole

mdl 72527 has been researched along with metronidazole in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (100.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Blanchard, Y; Chamaillard, L; Cipolla, B; Guillé, F; Havouis, R; Moulinoux, JP; Quemener, V	1

Other Studies

1 other study(ies) available for mdl 72527 and metronidazole

Article	Year
In vivo, synergestic inhibition of MAT-LyLu rat prostatic adenocarcinoma growth by polyamine deprivation and low-dose cyclophosphamide. Urological research, 1996, Volume: 24, Issue:2 Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Eflornithine; Lung Neoplasms; Male; Metronidazole; Neomycin; Oxidoreductases Acting on CH-NH Group Donors; Polyamines; Prostatic Neoplasms; Protein Synthesis Inhibitors; Putrescine; Rats; Rats, Inbred Strains; Survival Rate	1996

Article

Year

In vivo, synergestic inhibition of MAT-LyLu rat prostatic adenocarcinoma growth by polyamine deprivation and low-dose cyclophosphamide.

Urological research, 1996, Volume: 24, Issue:2

Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Eflornithine; Lung Neoplasms; Male; Metronidazole; Neomycin; Oxidoreductases Acting on CH-NH Group Donors; Polyamines; Prostatic Neoplasms; Protein Synthesis Inhibitors; Putrescine; Rats; Rats, Inbred Strains; Survival Rate

1996